Joshi SK, Huang A, Pittsenbarger J, Shinde U, Posso C, Piehowski PD, Gosline SJ, Press RD, Gritsenko MA, Hutchinson C, Weitz KK, Watanabe-Smith K, Long N, Rodland KD, Tyner JW, Druker BJ, Tognon CE. Oncogenic <i>NTRK3</i&gt; mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia. Haematologica; https://doi.org/10.3324/haematol.2024.285572 [Early view].